Welcome to our dedicated page for Nautilus Biotechnology news (Ticker: NAUT), a resource for investors and traders seeking the latest updates and insights on Nautilus Biotechnology stock.
Nautilus Biotechnology develops a single-molecule proteome analysis platform for measuring proteins and proteoforms across the human proteome. Company news centers on the Voyager™ Platform, Iterative Mapping, the Tau Proteoforms assay, early access customer activity, and collaborations that apply isoform-resolved proteomics to cancer and neurodegenerative disease research.
Updates also cover quarterly financial results, operating outlook, commercial-readiness activity, senior sales leadership, scientific conference presentations, and investor-conference participation. The company's disclosures frame Nautilus as a development-stage life sciences tools business moving its proteomics platform from validation and field evaluation toward broader customer access.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announced that it will disclose its financial results for the first quarter of 2023 on May 2, 2023, prior to the market opening. Management will host a conference call on the same day at 5:30 a.m. PT / 8:30 a.m. ET to discuss these results, along with business developments and future outlook. This will be streamed live on the company’s website. Nautilus is focused on developing a platform for protein analysis aiming to enhance the field of proteomics and improve human health outcomes.
Nautilus Biotechnology, a leader in single-molecule protein analysis, will participate in the B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics Virtual Conference on April 6, 2023. The management will feature in a fireside chat at 10:30 a.m. Pacific Time. Investors and interested individuals can tune in to a live and archived webcast on the company’s website. Nautilus aims to revolutionize proteomics by enhancing access to the proteome, fostering significant advancements in human health. To learn more, visit www.nautilus.bio.